Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Alemtuzumab (Campath®) and High Dose Interferon Beta-1a (Rebif®) Treatment on Cognition in Subjects With Relapsing Forms of MS

NCT00914758 is registered in ClinicalTrials.gov with Washington Neuropsychology Research Group as lead sponsor.

NCT NCT00914758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00914758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Alemtuzumab (Campath®) and High Dose Interferon Beta-1a (Rebif®) Treatment on Cognition in Subjects With Relapsing Forms of MS
Lead sponsor
Washington Neuropsychology Research Group
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2009
Completion date
December 31, 2011
Enrollment
1 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis